蛋白质组学在三阴性乳腺癌侵袭转移机制中的研究进展
2018-12-21罗雪莹何劲松陈伟财李锋刘宝儿
罗雪莹 何劲松 陈伟财 李锋 刘宝儿
[摘要] 三阴型乳腺癌(triple negative breast cancer,TNBC)为恶性程度最高、临床预后最差的乳腺癌亚型之一。其高侵袭转移能力是导致TNBC复发转移,改变患者临床预后的关键。基于人类基因组计划的完成,目前已认识到基因组水平并不能完全揭露TNBC肿瘤细胞各通路的作用机制。蛋白质组学作为新兴的研究手段,可以进行高通量筛选差异性表达蛋白质,完成相关肿瘤细胞恶性行为的功能学研究,探索TNBC高侵袭转移机制,为TNBC的临床诊疗研究提供了技术支持。该文旨在概述蛋白质组学在TNBC侵袭转移机制研究中的应用以及目前所取得的进展。
[关键词] 三阴性乳腺癌;蛋白质组学;侵袭转移机制;血管生成;细胞间粘附能力
[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-0742(2018)08(c)-0196-03
Advances in Proteomics in Invasion and Metastasis of Triple-negative Breast Cancer
LUO Xue-ying, HE Jin-song, CHEN Wei-cai, LI Feng, LIU Bo-er
Department of Breast Surgery, Shenzhen Hospital of Peking University, Shenzhen, Guangdong Province, 518000 China
[Abstract] Triple negative breast cancer (TNBC) is one of the most malignant breast cancer subtypes. Its high invasion and metastasis capacity is the key to the recurrence and metastasis of TNBC, which changes the clinical prognosis of patients. Based on the completion of the Human Genome Project, it has now been recognized that the genome level does not fully reveal the mechanism of action of TNBC tumor cell pathways. As an emerging research method, proteomics can perform high-throughput screening for differentially expressed proteins, complete the functional study of malignant behavior of related tumor cells, and explore the mechanism of high invasion and metastasis of TNBC, providing technical support for the clinical diagnosis and treatment of TNBC. This article aims to outline the application of proteomics in the study of the invasion and metastasis mechanism of TNBC and the current progress.
[Key words] Triple negative breast cancer; Proteomics; Invasion and metastasis mechanism; Angiogenesis; Intercellular adhesion
TNBC为乳腺癌的一种特殊类型,其雌激素受体、孕激素受体不表达,人表皮生长因子受体2无过度表达及基因扩增[1]。它多发生于绝经前女性,约占乳腺癌患者的13%~25%,其细胞分化差,侵袭性强,好发年龄小,恶性程度高,缺乏高特异性的评估方法,极易复发转移,临床预后差。而肿瘤细胞的高侵袭转移行为则是TNBC不良预后的关键性因素。蛋白质作为生物学功能的执行者,调控细胞恶性行为方面发挥着重要作用。进行蛋白质组功能学研究可以更好地从宏观的角度全面重点地分析TNBC高侵袭转移的生物学机制。
1 肿瘤内部微血管网的形成
微血管网络生成除了给肿瘤细胞提供氧气和营养物质、促进细胞增殖分化以外,其与恶性肿瘤细胞的侵袭转移密切相关。……
